Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
01 juin 2022 07h30 HE
|
Annexon Biosciences
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
Annexon Biosciences
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023...
Annexon Biosciences to Participate in Upcoming May Investor Conferences
05 mai 2022 06h30 HE
|
Annexon Biosciences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
07 avr. 2022 06h30 HE
|
Annexon Biosciences
BRISBANE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
04 avr. 2022 06h30 HE
|
Annexon Biosciences
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
03 mars 2022 16h01 HE
|
Annexon Biosciences
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
01 mars 2022 16h01 HE
|
Annexon Biosciences
Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Huntington’s Disease; Full Data...
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
28 févr. 2022 06h30 HE
|
Annexon Biosciences
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
20 janv. 2022 06h30 HE
|
Annexon Biosciences
BRISBANE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
04 janv. 2022 16h05 HE
|
Annexon Biosciences
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and...